Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Nilotinib can cause keratosis pilaris, a skin condition.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Improved CRBN ligands make protein degraders more effective and drug-like.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Upadacitinib effectively treated severe hair loss in a child.

Upadacitinib effectively treats psoriasis and lichen planus together.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Promising cancer treatments were found, but the manufacturer closed.

Upadacitinib may effectively treat alopecia areata without side effects.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.